ArticleScientific reports2025
Integrative in Silico and in vitro validation suggest LINC00963 and SNHG15 as candidate biomarkers for coronary artery disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite notable advancements in prevention, medication, and treatment approaches, coronary artery disease (CAD) remains a significant challenge for healthcare systems and the economy. In relation to CAD, long non-coding RNAs (lncRNAs) can impact its development by influencing immune responses, affecting the functions of endothelial and vascular smooth muscle cells, and modifying lipid metabolism. Through the analysis of the GEO dataset (GSE42148), we identified differentially expressed genes (DEGs) and lncRNAs (DELs) in CAD patients. We performed functional enrichment and pathway analyses to clarify the roles of these DEGs. To investigate the interactions between DEGs and DELs, we created the lncRNA-mRNA interaction network. To investigate the interactions between DEGs and DELs, we constructed an lncRNA-mRNA interaction network. Candidate lncRNAs were validated by real-time PCR using peripheral blood from CAD patients. Our in vitro study confirmed that LINC00963 and SNHG15 were upregulated in CAD patients compared to the control group. Notably, LINC00963 levels were significantly elevated in patients with a positive family history, hyperlipidemia, hypertension, and diabetes, while SNHG15 expression was higher in smokers. Additionally, a significant negative correlation was found between the expressions of LINC00963 and SNHG15 and the age of the individuals. ROC curve analysis indicated that both lncRNAs have high sensitivity and specificity as biomarkers. Furthermore, this study suggests that LINC00963 and SNHG15 could serve as valuable markers for the early detection of CAD, particularly in younger individuals. It is proposed that these lncRNAs are associated with inflammatory conditions in CAD. Overall, LINC00963 and SNHG15 may act as promising early detection markers for CAD based on bioinformatics and peripheral blood-based validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.